The Best Smart Rings Of 2026, Picked After Months Of Testing - Forbes
·Sep 5, 2026
Source: Forbes
Read the original article This article is an excerpt. To read the full content, visit the original source. Forbes
Reactions
Related articles
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
Oncodaily·
0 comments
No comments yet. Be the first to share your thoughts!